Lux Biosciences, Inc.

MENLO PARK, Calif.--(BUSINESS WIRE)-- ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors. Mr. Mitchell is a highly experienced and well-regarded biotechnology and pharmaceutical industry veteran who brings over three decades of experience as a board director and corporate executive to the ReCode board. “We are delighted to have Dean join the board as we continue to advance our respiratory clinical development programs and leverage our novel SORT LNP delivery platform to expand our portfolio,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics. “His proven track record at growing and scaling biopharma companies is a welcome addition to our board that will support the company’s near- and long-term growth.” “I am pleased to join the talented ReCode board at a pivotal time for the company as it continues to achieve significant milestones for its lead clinical programs and expand its research and discovery efforts into gene correction,” said Mr. Mitchell. “I look forward to working with the board and the executive team to advance these novel therapies with the goal of one day providing much-needed treatments for patients living with rare diseases.” Mr. Mitchell currently serves as chairman of the Board of Directors of Praxis Precision Medicines, Inc., an appointment he has held since 2020, and as a board director for Theravance Biopharma, Inc. (since 2014) and Precigen (since 2009). Mr. Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024. He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018. Mr. Mitchell previously held the position of president and chief executive officer at Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, at Alpharma, Inc., a publicly traded specialty pharmaceutical company until its acquisition by King Pharmaceuticals, Inc., and at Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused on oncology and acute care, until its acquisition by MGI Pharma Inc. He previously held executive roles at Bristol Myers Squibb and GlaxoSmithKline. Mr. Mitchell earned a B.A. from City University London and a B.Sc. in biology from Coventry University. About ReCode Therapeutics ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver, and infectious disease indications. ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit and follow us on LinkedIn and Instagram.

New York, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anterior Uveitis Treatment Market Research Report by Treatment Type, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19" - Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Anterior Uveitis Treatment Market is expected to grow from USD 201.59 Million in 2020 to USD 289.82 Million by the end of 2025.2. The Global Anterior Uveitis Treatment Market is expected to grow from EUR 176.75 Million in 2020 to EUR 254.11 Million by the end of 2025.3. The Global Anterior Uveitis Treatment Market is expected to grow from GBP 157.13 Million in 2020 to GBP 225.91 Million by the end of 2025.4. The Global Anterior Uveitis Treatment Market is expected to grow from JPY 21,514.76 Million in 2020 to JPY 30,931.13 Million by the end of 2025.5. The Global Anterior Uveitis Treatment Market is expected to grow from AUD 292.73 Million in 2020 to AUD 420.85 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Anterior Uveitis Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Treatment Type, the Anterior Uveitis Treatment Market studied across Anti-TNF Agents, Corticosteroids, Cycloplegic Agents, and Immunosuppressants. Based on Distribution Channel , the Anterior Uveitis Treatment Market studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Based on Geography, the Anterior Uveitis Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Anterior Uveitis Treatment Market including AbbVie Inc., Aciont Inc., Akorn Pvt. Ltd, Aldeyra Therapeutics, Inc., Alimera Sciences Inc., Amdipharm Mercury Company Limited, Amgen Inc., Bausch & Lomb Incorporated, Clearside Biomedical, Inc., Enzo Biochem Inc, Enzo Biochem Inc., Eyegate Pharmaceuticals, Inc., Hanall Biopharma, Lux Biosciences, Inc, Novartis AG, Ophthalix Inc, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co. Ltd, Sirion Therapeutics, Inc., TopiVert Pharma Limited, UAB Medicine, UCB Biopharma S.P.R.L., Wize Pharma Inc, and Xoma Corporation. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anterior Uveitis Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Anterior Uveitis Treatment Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anterior Uveitis Treatment Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anterior Uveitis Treatment Market?4. What is the competitive strategic window for opportunities in the Global Anterior Uveitis Treatment Market?5. What are the technology trends and regulatory frameworks in the Global Anterior Uveitis Treatment Market?6. What are the modes and strategic moves considered suitable for entering the Global Anterior Uveitis Treatment Market?Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that Brett Skolnik, Chief Financial Officer, will present a company overview at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18th, 2009 at 10:00 a.m. ET. The conference is ongoing November 17–19 at the St. Regis Hotel, New York City.